| IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has announced a strategic collaboration with the contract research organization arm of Sarah Cannon Research Institute, SCRI Development Innovations, aimed at transforming oncology trials for biopharma partners worldwide. By combining the capabilities of IQVIA and SCRI Development. |
businesswire.com |
2025-05-16 12:00:00 |
Czytaj oryginał (ang.) |
| Investing in IQVIA (IQV)? Don't Miss Assessing Its International Revenue Trends |
Evaluate IQVIA's (IQV) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance. |
zacks.com |
2025-05-13 14:23:17 |
Czytaj oryginał (ang.) |
| IQVIA: Q1 Earnings Support Steady Optimism |
IQVIA Holdings reported strong Q1 earnings with $3.83B in revenue, driven by growth in the Technology & Analytics Solutions segment, despite market pessimism. The company's profitability remains robust with adjusted EBITDA of $883M and a 6.3% increase in adjusted EPS, supported by high cash flow conversion. IQVIA's active share repurchase program and raised full-year revenue guidance highlight management's confidence in weathering sector volatility and macroeconomic headwinds. |
seekingalpha.com |
2025-05-09 17:48:59 |
Czytaj oryginał (ang.) |
| IQVIA CFO Ron Bruehlman to speak at the Bank of America Annual Health Care Conference on May 13 |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Bank of America Annual Health Care Conference on Tuesday, May 13, 2025, at 5:20 p.m. ET (2:20 p.m. local PT). A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA. |
businesswire.com |
2025-05-07 20:15:00 |
Czytaj oryginał (ang.) |
| IQVIA (IQV) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates |
The headline numbers for IQVIA (IQV) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-05-07 02:00:29 |
Czytaj oryginał (ang.) |
| IQVIA Holdings Inc. (IQV) Q1 2025 Earnings Call Transcript |
IQVIA Holdings Inc. (NYSE:IQV ) Q1 2025 Earnings Conference Call May 6, 2025 9:00 AM ET Company Participants Kerri Joseph - Senior Vice President, Investor Relations and Treasury Ari Bousbib - Chief Executive Officer Ron Bruehlman - Chief Financial Officer Mike Fedock - Senior Vice President, Financial Planning and Analysis Conference Call Participants Justin Bowers - Deutsche Bank Matthew Sykes - Goldman Sachs Shlomo Rosenbaum - Stifel Financial Corp. Michael Ryskin - Bank of America Jailendra Singh - Truist Securities Eric Coldwell - Robert W. Baird & Co. David Windley - Jefferies Group LLC Tejas Savant - Morgan Stanley Operator Ladies and gentlemen, thank you for standing by. |
seekingalpha.com |
2025-05-06 19:04:08 |
Czytaj oryginał (ang.) |
| IQVIA Earnings & Revenues Beat Estimates in Q1, Increase Y/Y |
IQV's top line in the first quarter of 2025 benefits from the Research and Development, and Technology and Analytics segments. |
zacks.com |
2025-05-06 17:35:15 |
Czytaj oryginał (ang.) |
| IQVIA Holdings (IQV) Surpasses Q1 Earnings and Revenue Estimates |
IQVIA Holdings (IQV) came out with quarterly earnings of $2.70 per share, beating the Zacks Consensus Estimate of $2.63 per share. This compares to earnings of $2.54 per share a year ago. |
zacks.com |
2025-05-06 13:10:42 |
Czytaj oryginał (ang.) |
| IQVIA Reports First-Quarter 2025 Results |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended March 31, 2025. First-Quarter 2025 Operating Results Revenue for the first quarter of $3,829 million increased 2.5 percent on a reported basis and 3.5 percent at constant currency, compared to the first. |
businesswire.com |
2025-05-06 11:00:00 |
Czytaj oryginał (ang.) |
| Life Science Analytics Market worth $68.81 billion by 2030 11.4% CAGR | MarketsandMarkets™ |
DELRAY BEACH, Fla., May 2, 2025 /PRNewswire/ -- The global Life Science Analytics Market , valued at US$35.69 billion in 2024, is forecasted to grow at a robust CAGR of 11.4%, reaching US$40.03 billion in 2025 and an impressive US$68.81 billion by 2030. The standardization of diverse datasets from sources such as clinical trials, electronic health records (EHRs), genomics, and real-world evidence is essential for the efficient exchange of information across various platforms and geographical regions. This standardization enhances multi-site clinical trials and cross-border research collaborations. Additionally, emerging technologies like artificial intelligence (AI), quantum computing, and cognitive computing play a vital role in transforming large volumes of raw data into actionable insights. These technologies help simplify reports and create interactive dashboards. Furthermore, the increasing adoption of analytics in pre-clinical trials, drug discovery, and clinical trials, particularly for applications such as patient recruitment and site identification, helps to reduce the workload for researchers and investigators. These factors contribute significantly to the growing adoption of analytics across the life sciences industry. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174990653 Browse in-depth TOC on "Life Science Analytics Market" 100 - Tables50 - Figures500 - Pages By Based on type, the life science analytics services market is categorized into two main types: managed services and professional services. In 2024, the managed services segment held the largest share of the life science analytics market. This significant share is largely due to the increasing demand for advanced insights, the need for cost-effective drug development, technological advancements in the industry, and the necessity for ongoing support in strategic decision-making. These factors make outsourcing analytics and consulting more attractive for life science companies. Leading companies in the field offer consulting services that leverage data and analytics to evaluate opportunities, design analytics strategies, and implement appropriate technology solutions. For instance, in May 2023, SAS Institute (US) partnered with HTEC (US) to deliver strategic analytics consulting services across various sectors, including life sciences and healthcare. By Based on applications, The life science analytics market is divided into several applications, including research & development, commercial analytics, regulatory compliance, manufacturing and supply chain optimization, and safety. In 2024, the research & development segment held the largest share of this market. This significant share is mainly due to its capacity to accelerate drug discovery, optimize clinical trials, and improve research accuracy through advanced data analysis and AI-driven insights. Additionally, factors such as increasing R&D expenditure in the pharmaceutical and biopharmaceutical sectors, a rise in patent expirations and declining drug pipelines, and a growing focus on personalized medicine and precision therapeutics are further driving growth in this segment. By geography, the life science analytics market is divided into five primary regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is expected to experience significant growth, with a noticeable annual growth rate during the forecast period. Key factors driving the expansion of life science analytics solutions in this region include a gradual shift towards adopting advanced technologies such as automation, artificial intelligence (AI), and machine learning (ML). Additionally, rising investments are attracting new market players, and the presence of leading educational institutions and research centers in Asia Pacific is fostering scientific innovation and technological advancement. Furthermore, increased direct investments from pharmaceutical and biotechnology companies in Europe and North America are anticipated to boost the adoption of life science analytics solutions in Asia. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=174990653 Oracle (US), Merative (formerly IBM) (US), SAS Institute (US), Accenture (Ireland), IQVIA (US), Cognizant (US), Wipro (India), Veradigm (US), Optum (US), Microsoft (US), MaxisIT (US), ExlService Holdings (US), Inovalon (US), CitiusTech (US), Saama (US), Axtria (US), Clarivate (UK), ThoughtSphere (US), ThoughtSpot (US), Salesforce (US), Google LLC (US), Amazon Web Services, Inc. (US), Veeva Systems (US), Elsevier (Netherlands), and Komodo Health, Inc. (US) are the major players in this market. These companies mainly focus on strategies such as acquisitions, collaborations, partnerships, expansion, and product launches and updates to remain competitive and further increase their share in the market. ORACLE (US): Oracle (US) is a leading company in life science analytics worldwide. The company offers analytics software and services for various applications, including research & development, commercialization, and more. Oracle is committed to continuously updating its products to meet customer expectations. Additionally, the company invests in expanding its solutions through partnerships and collaborations, ensuring tailored solutions for its users. In March 2025, Oracle partnered with Huntsville Hospital Health System (US) to standardize its Oracle Health Foundation electronic health record system across all facilities. This collaboration aims to provide consistent, high-quality care and a unified experience for both patients and providers as they move between different locations. With a broad customer base and a significant geographic presence, Oracle is a critical player in various IT software, hardware, and service markets, including life science analytics. MERATIVE (US): Merative (US) is another leading player in the life science analytics market. The company offers a comprehensive suite of informatics products and services tailored for life science analytics. By leveraging advanced technologies such as AI and ML, Merative enhances the accuracy and efficiency of evidence analysis. Its strong brand recognition and extensive product portfolio have significantly contributed to its success. Merative serves various sectors, including life science systems, clinical trial sponsors, and the medical device manufacturing industry. Additionally, the company has established offices across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. SAS INSTITUTE INC. (US) SAS Institute Inc. (US) is a company that specializes in analytics software and services. It offers a wide range of solutions, including advanced analytics, business intelligence, cloud analytics, customer intelligence, data operations, data management, decision management, fraud and security intelligence, in-memory analytics, performance management, risk management, and supply chain management. These solutions enable organizations to access, manage, analyze, and report on data to support informed decision-making. SAS Institute serves various industries, including communications, education, financial services, government, health insurance, healthcare, hospitality, insurance, life sciences, manufacturing, media, oil and gas, retail, travel and transportation, and utilities. Through its Life Sciences industry segment, the company also provides specialized analytics solutions for the life sciences sector. By leveraging AI and analytics driven by fast and relevant data, SAS aims to propel innovation in health and life sciences. The company supports customers in 146 countries across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. More than 82,000 business, government, and university sites utilize SAS OnDemand for Academics. For more information, Inquire Now! Related Reports: Healthcare Analytics Market Healthcare BPO Market Healthcare IT Market Artificial Intelligence (AI) in Healthcare Market Healthcare Data Monetization Market Get access to the latest updates on Life Science Analytics Companies and Life Science Analytics Market Size About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected]Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg |
https://www.prnewswire.com |
2025-05-02 14:30:00 |
Czytaj oryginał (ang.) |
| Landmark Science Makes RWE Services for Biopharma Industry a Boutique Experience |
LOS ANGELES, May 2, 2025 /PRNewswire/ -- Landmark Science, a premier provider of real-world evidence (RWE) solutions, is redefining industry standards with its white-glove, high-touch approach to evidence generation. With long-standing roots in biopharma, Landmark Science bridges the gap between vendors and biopharma, delivering agile and efficient solutions uniquely tailored to clients. This hand-held approach through and through helps clients avoid typical red tape situations that can delay or halt critical evidence generation to swiftly transform evidence into insights on patient care, access, and outcomes. Landmark Science founder and CEO, Shivani Aggarwal, PhD, MS, brings 15 years of experience in RWE and clinical trials from her time at leading life science companies Amgen, Regeneron, and IQVIA. With deep scientific acumen and a strong track record in evidence generation, Shivani Aggarwal drives Landmark Science's strategic vision, spearheading the delivery of innovative, data-driven solutions to help patients. "Our approach goes beyond traditional evidence generation—we partner closely with our clients to provide tailored, high-touch support that meets their unique needs," says Shivani Aggarwal. "By combining deep industry expertise with cutting-edge methodologies, we empower biopharma organizations with impactful insights that drive innovation and regulatory success at exceptional speed." With a team of seasoned epidemiologists and advanced statistical programmers, Landmark Science offers bespoke solutions with a comprehensive suite of services, including data landscaping, full-scale RWE studies, and advanced analytics. Landmark Science brings unparalleled expertise to some of the most complex therapeutic areas and offers pan-therapeutic solutions to provide invaluable support across various disease areas including hematology, oncology, immunology, and rare disease. The company leverages its extensive experience to help clients successfully navigate the rapidly evolving RWE landscape. As the demand for high-quality, real-world evidence grows, Landmark Science stands at the forefront, ensuring its clients receive rigorous scientific insights and the highest personalized service. About Landmark Science, Inc. Landmark Science, Inc. is a premier life science research organization providing real-world evidence and health outcomes research solutions. The company provides a comprehensive suite of services enabling the use of RWE in drug development. Landmark Science's team of experts deliver RWE for clinical program strategy, health economics, commercial, market access, and regulators and payors to meet diverse needs efficiently. Specialties include complex study designs used to support regulatory submissions, therapeutic area expertise, and data landscaping. To learn more, please visit www.landmarkscience.com or contact [email protected]. Media Contact:Landmark Science[email protected]+1 (424) 535-3011https://landmarkscience.com/ |
https://www.prnewswire.com |
2025-05-02 14:04:00 |
Czytaj oryginał (ang.) |
| IQVIA Gears Up to Report Q1 Earnings: What's in Store for the Stock? |
Growth across the R&DS and TAS segments is anticipated to have boosted IQV's top line in the first quarter of 2025. |
zacks.com |
2025-05-01 14:35:42 |
Czytaj oryginał (ang.) |
| IQVIA (IQV) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures |
Evaluate the expected performance of IQVIA (IQV) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. |
zacks.com |
2025-05-01 14:21:00 |
Czytaj oryginał (ang.) |
| IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy? |
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-29 15:07:34 |
Czytaj oryginał (ang.) |
| IQVIA celebrates Marie E. Lamont and Dr. Joanne Hackett, winners of Healthcare Businesswomen's Association Awards |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Marie E. Lamont, head of Real World Solutions (Patient Insights, Experience and Registry Solutions), and Dr. Joanne Hackett, vice president, Health System Services (Europe, Middle East, Africa and South Asia), have been honored by the Healthcare Businesswomen. |
businesswire.com |
2025-04-28 13:00:00 |
Czytaj oryginał (ang.) |
| IQVIA named a front-runner in generative AI innovation by global industry research and analysis firm |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced today that the global independent research and analysis firm Everest Group® has named IQVIA a “front-runner generative AI leader” for the life sciences industry in its recent report, “AI-deas to Action: Operationalizing Generative AI in Life Sciences.” IQVIA was the only clinical research organization to receive the. |
businesswire.com |
2025-04-23 13:00:00 |
Czytaj oryginał (ang.) |
| IQVIA to Announce First-Quarter 2025 Results on May 6, 2025 |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its first-quarter 2025 financial results before the market opens on Tuesday, May 6, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slid. |
businesswire.com |
2025-04-21 20:15:00 |
Czytaj oryginał (ang.) |
| Stabilization and improvement seen in multiple key biopharma R&D metrics, says IQVIA Institute Report |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--The life sciences innovation ecosystem continued to evolve and expand in 2024 as the industry continued to adapt to a complex and dynamic range of geopolitical, technological and social uncertainties. The year saw progress in funding, trial starts, program productivity and cycle times, according to the new report, Global Trends in R&D 2025: Progress in Recapturing Innovation in Biopharma Innovation, released by the IQVIA Institute for Human Dat. |
businesswire.com |
2025-04-15 12:00:00 |
Czytaj oryginał (ang.) |
| IQVIA (IQV) Moves 8.7% Higher: Will This Strength Last? |
IQVIA (IQV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2025-04-10 15:45:46 |
Czytaj oryginał (ang.) |
| Here's Why Investors Must Hold IQV Stock in Their Portfolios Now |
The IQV stock is benefiting from partner retention, acquisition and investment in AI-led innovation. |
zacks.com |
2025-03-26 13:55:31 |
Czytaj oryginał (ang.) |
| Global Healthy Living Foundation and IQVIA Institute Report Millions of Adult Vaccines Likely Missed When States Restrict Pharmacist Participation |
UPPER NYACK, N.Y.--(BUSINESS WIRE)--When pharmacists can't give adult vaccinations, millions of people go without them. |
businesswire.com |
2025-02-25 17:00:00 |
Czytaj oryginał (ang.) |
| IQVIA Holdings (IQV) is a Top-Ranked Value Stock: Should You Buy? |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-02-25 12:40:50 |
Czytaj oryginał (ang.) |
| IQVIA AI Assistant wins 2024 PM360 Innovation Award for Artificial Intelligence |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences and healthcare industries, today announced that IQVIA AI Assistant has been awarded a 2024 PM360 Innovation Award in the Artificial Intelligence category. Launched in September 2024, IQVIA AI Assistant revolutionizes insight generation by providing rapid, relevant and precise answers to complex business questio. |
businesswire.com |
2025-02-24 11:00:00 |
Czytaj oryginał (ang.) |
| IQVIA CFO Ron Bruehlman to Speak at the TD Cowen Annual Health Care Conference on March 4, 2025 |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the TD Cowen Annual Health Care Conference on Tuesday, March 4, 2025, at 11:10 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is a lead. |
businesswire.com |
2025-02-21 11:00:00 |
Czytaj oryginał (ang.) |
| IQVIA Releases 2024 Sustainability Report |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has published its 2024 Sustainability Report. The report details IQVIA's sustainability achievements consistent with its mission to accelerate innovation for a healthier world. “IQVIA combines technology and scientific expertise with our unique information assets and Healthcare-gr. |
businesswire.com |
2025-02-20 12:06:00 |
Czytaj oryginał (ang.) |
| NVIDIA's Rise Puts These 3 Healthcare Stocks in the Spotlight |
ILMN, IQV and DXCM are leveraging AI advancements to drive innovation in genomics, clinical research and diabetes management. |
zacks.com |
2025-02-18 15:36:09 |
Czytaj oryginał (ang.) |
| IQVIA: Revenues, Net Profit Margin, And A Positive Long-Term Outlook Will Pave The Way |
IQVIA has seen an increase of 58.97% in its revenues since 2017. In addition, its net profit margin has strengthened since 2018. The CRO market expects to grow at a 7.42% CAGR between 2024 and 2033, which indicates that the Research & Development Solutions segment of IQVIA will have a positive outlook. IQVIA has an enormous dataset, with 1,200 million registers. This dataset has been crucial for developing artificial intelligence and data analytics solutions in the upcoming years. |
seekingalpha.com |
2025-02-16 05:36:57 |
Czytaj oryginał (ang.) |
| IQVIA (IQV) International Revenue Performance Explored |
Explore how IQVIA's (IQV) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects. |
zacks.com |
2025-02-14 12:15:30 |
Czytaj oryginał (ang.) |
| IQVIA Earnings & Revenues Surpass Estimates in Q4, Increase Y/Y |
Growth in the Research and Development, and Technology and Analytics segments aids IQV's top line in the fourth quarter of 2024. |
zacks.com |
2025-02-06 15:51:11 |
Czytaj oryginał (ang.) |
| IQVIA Holdings Inc. (IQV) Q4 2024 Earnings Call Transcript |
IQVIA Holdings Inc. (NYSE:IQV ) Q4 2024 Earnings Conference Call February 6, 2025 9:00 AM ET Company Participants Kerri Joseph – Senior Vice President, Investor Relations and Treasury Ari Bousbib – Chairman and Chief Executive Officer Ron Bruehlman – Executive Vice President and Chief Financial Officer Conference Call Participants Shlomo Rosenbaum – Stifel Elizabeth Anderson – Evercore ISI Ann Hynes – Mizuho David Windley – Jefferies Charles Rhyee – TD Cowen Jack Meehan – Nephron Research Michael Ryskin – Bank of America Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the IQVIA Fourth Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2025-02-06 13:58:53 |
Czytaj oryginał (ang.) |
| IQVIA Delivers Solid Q4 Growth Despite 'Choppy' Market Conditions |
On Thursday, IQVIA Holdings Inc IQV reported a fourth adjusted EPS of $3.12, up from $2.84, beating the consensus of $3.11. |
benzinga.com |
2025-02-06 13:37:53 |
Czytaj oryginał (ang.) |
| Here's What Key Metrics Tell Us About IQVIA (IQV) Q4 Earnings |
Although the revenue and EPS for IQVIA (IQV) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-02-06 12:36:49 |
Czytaj oryginał (ang.) |
| IQVIA Holdings (IQV) Beats Q4 Earnings and Revenue Estimates |
IQVIA Holdings (IQV) came out with quarterly earnings of $3.12 per share, beating the Zacks Consensus Estimate of $3.10 per share. This compares to earnings of $2.84 per share a year ago. |
zacks.com |
2025-02-06 11:10:27 |
Czytaj oryginał (ang.) |
| IQVIA beats quarterly results estimates on analytics services demand |
Contract research firm IQVIA Holdings beat Wall Street estimates for fourth-quarter profit and revenue on Thursday, helped by the demand for its healthcare data and analytics services. |
reuters.com |
2025-02-06 10:34:22 |
Czytaj oryginał (ang.) |
| IQVIA Reports Fourth-Quarter and Full-Year 2024 Results; Reaffirms Full-Year 2025 Guidance |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended December 31, 2024. "IQVIA delivered excellent fourth quarter performance, closing out a strong 2024," said Ari Bousbib, chairman and CEO of IQVIA. "R&DS revenue was on target and bookings exceeded o. |
businesswire.com |
2025-02-06 09:00:00 |
Czytaj oryginał (ang.) |
| IQVIA Gears Up to Report Q4 Earnings: What's in Store for the Stock? |
IQV's top line in the fourth quarter of 2024 is expected to have benefited from the rising use of GenAI to provide crucial insights. |
zacks.com |
2025-02-05 15:45:36 |
Czytaj oryginał (ang.) |
| IQVIA named to the Fortune® World's Most Admired Companies™ list, ranked No. 1 in its sector for fourth consecutive year |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, was named No. 1 in its category on the 2025 Fortune® World's Most Admired Companies™ list. This is the fourth year in a row IQVIA has earned first place in the Health Care: Pharmacy and Other Services category, and the eighth consecutive year it has appeared on the list. Notably, IQVIA earned first place in its category on fou. |
businesswire.com |
2025-02-04 13:00:00 |
Czytaj oryginał (ang.) |
| Here's Why IQVIA Holdings (IQV) is a Strong Value Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-02-04 12:40:54 |
Czytaj oryginał (ang.) |
| IQVIA Holdings (IQV) is a Top-Ranked Momentum Stock: Should You Buy? |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-02-03 12:50:18 |
Czytaj oryginał (ang.) |
| Unlocking Q4 Potential of IQVIA (IQV): Exploring Wall Street Estimates for Key Metrics |
Evaluate the expected performance of IQVIA (IQV) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. |
zacks.com |
2025-02-03 12:21:22 |
Czytaj oryginał (ang.) |
| IQVIA Benefits From Global IT Infrastructure Amid Low Liquidity |
The IQV stock gains from its $330-billion addressable market and an enormous trove of data, which is its distinguishing asset. |
zacks.com |
2025-01-03 15:16:53 |
Czytaj oryginał (ang.) |
| IQVIA (IQV) Surges 3.0%: Is This an Indication of Further Gains? |
IQVIA (IQV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2024-12-23 13:21:09 |
Czytaj oryginał (ang.) |
| Digital Health Tools are Expanding in Scope and Function to Aid Patient Diagnosis, Treatment and Monitoring, Says New Report from The IQVIA Institute |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Despite a drop in venture funding for digital health companies over the last two-and-a-half years, digital health products and solutions are expanding in scope and function to aid patient diagnosis, treatment, and monitoring. More solutions are now focused on specific diseases, and their commercial appeal has grown as developers build solutions that bring value back to providers, are more easily integrated with health systems, and embrace innovatio. |
businesswire.com |
2024-12-23 10:00:00 |
Czytaj oryginał (ang.) |
| Iqvia initiated with an Overweight at Stephens |
Stephens initiated coverage of Iqvia with an Overweight rating and $250 price target. The firm says the company has "fulfilled the promise" of combining a leading contract research organization and the largest life science data repository to connect intelligence that advances healthcare. The analyst views the company's Q3 reset, as well as the recent outline of "reasonably conservative" fiscal 2025 and long-term growth frameworks, as creating an attractive setup "for a well-run industry bellwether." |
https://thefly.com |
2024-12-19 18:26:48 |
Czytaj oryginał (ang.) |
| IQVIA Holdings: Share Price Disconnected From Growth Outlook |
IQVIA continues to outperform earnings expectations, despite a 14% stock decline, driven by concerns of a CRO industry slowdown and reduced early-stage R&D spending. Q3 results show strong performance with $3.9B revenue, 14.1% EPS growth, and a $31.1B backlog, reinforcing long-term growth potential. Analysts project slower CRO growth, but IQVIA's leadership, consistent earnings, and long-term revenue estimates of $28.45B by 2033 support a bullish outlook. |
seekingalpha.com |
2024-12-12 10:29:44 |
Czytaj oryginał (ang.) |
| Why You Should Retain IQVIA Holdings Stock in Your Portfolio Now |
IQV is known for its innovative use of technology and data analytics. |
zacks.com |
2024-11-28 15:05:46 |
Czytaj oryginał (ang.) |
| Interpreting IQVIA (IQV) International Revenue Trends |
Evaluate IQVIA's (IQV) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance. |
zacks.com |
2024-11-04 12:22:35 |
Czytaj oryginał (ang.) |
| IQVIA (IQV) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates |
While the top- and bottom-line numbers for IQVIA (IQV) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2024-10-31 23:31:11 |
Czytaj oryginał (ang.) |
| IQVIA Holdings Inc. (IQV) Q3 2024 Earnings Call Transcript |
IQVIA Holdings Inc. (NYSE:IQV ) Q3 2024 Results Conference Call October 31, 2024 9:00 AM ET Company Participants Kerri Joseph - Senior Vice President, Investor Relations & Treasury Ari Bousbib - Chairman and Chief Executive Officer Ron Bruehlman - Executive Vice President and Chief Financial Officer Eric Sherbet - Executive Vice President and General Counsel Mike Fedock - Senior Vice President, Financial Planning and Analysis Gustavo Peroni - Senior Director, Investor Relations Conference Call Participants Ann Hynes - Mizuho Shlomo Rosenbaum - Stifel Anne Samuel - JP Morgan Luke Sergott - Barclays Bank Justin Bowers - Deutsche Bank David Windley - Jefferies Elizabeth Anderson - Evercore ISI Michael Cherny – Leerink Partners Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the IQVIA Third Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-10-31 17:52:08 |
Czytaj oryginał (ang.) |
| IQVIA Earnings & Revenues Surpass Estimates in Q3, Increase Y/Y |
Strength in the Research and Development, and Technology and Analytics segments drives IQV's top line in the third quarter of 2024. |
zacks.com |
2024-10-31 16:15:20 |
Czytaj oryginał (ang.) |
| IQVIA lowers annual revenue forecast amid trial delays |
Contract research firm IQVIA lowered its annual revenue forecast on Thursday, due to delays in two clinical trials as one of its clients faces logistical challenges. |
reuters.com |
2024-10-31 14:50:50 |
Czytaj oryginał (ang.) |
| IQVIA Holdings (IQV) Q3 Earnings and Revenues Beat Estimates |
IQVIA Holdings (IQV) came out with quarterly earnings of $2.84 per share, beating the Zacks Consensus Estimate of $2.81 per share. This compares to earnings of $2.49 per share a year ago. |
zacks.com |
2024-10-31 11:16:11 |
Czytaj oryginał (ang.) |
| IQVIA Reports Third-Quarter 2024 Results and Announces Investor Day |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended September 30, 2024. Third-Quarter 2024 Operating Results Revenue for the third quarter of $3,896 million increased 4.3 percent on a reported basis and 4.2 percent at constant currency, compared to the t. |
businesswire.com |
2024-10-31 09:00:00 |
Czytaj oryginał (ang.) |
| IQVIA Gears Up to Report Q3 Earnings: Here's What You Should Know |
IQV's TAS and RD&S revenues are anticipated to have increased, while CSMS revenues are likely to have dipped in the third quarter of 2024. |
zacks.com |
2024-10-28 14:51:31 |
Czytaj oryginał (ang.) |
| Seeking Clues to IQVIA (IQV) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics |
Besides Wall Street's top -and-bottom-line estimates for IQVIA (IQV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024. |
zacks.com |
2024-10-28 12:20:51 |
Czytaj oryginał (ang.) |
| IQVIA Holdings (IQV) Reports Next Week: Wall Street Expects Earnings Growth |
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-24 15:06:13 |
Czytaj oryginał (ang.) |
| IQVIA to Announce Third-Quarter 2024 Results on October 31, 2024 |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its third-quarter 2024 financial results before the market opens on Thursday, October 31, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentatio. |
businesswire.com |
2024-10-15 20:15:00 |
Czytaj oryginał (ang.) |
| Here's Why You Should Retain IQVIA Holdings Shares Now |
While IQV benefits from its market leadership, data-driven innovation and global expansion, it must navigate pricing pressure. |
zacks.com |
2024-10-04 16:51:07 |
Czytaj oryginał (ang.) |
| Here's Why IQVIA Holdings (IQV) is a Strong Value Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2024-10-04 14:47:13 |
Czytaj oryginał (ang.) |
| IQVIA AI Solution Receives 2024 Frost & Sullivan Global Customer Value Leadership Award |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced that Frost & Sullivan, a leading independent research and consulting firm, has awarded IQVIA with the 2024 Global Customer Value Leadership Award for excellence in the global artificial intelligence (AI) quality and regulatory solutions space for the healthcare industry. Frost &am. |
businesswire.com |
2024-09-19 13:00:00 |
Czytaj oryginał (ang.) |